The Latest Cardiac and Vascular News
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity Post this “2024 is off to a […]
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. “The data highlights the opportunities to improve care, but it will take a sustained partnership among hospital […]
CHAPEL HILL, N.C., May 2, 2024 /PRNewswire/ — SonoVascular, Inc., a private medical device company focused on the development of its SonoThrombectomy™ System, a novel pharmaco-mechanical ultrasound facilitated thrombectomy system that utilizes microbubble-mediated cavitation as a core…
CARLSBAD, Calif., May 2, 2024 /PRNewswire/ — MedRes International, Inc. is pleased to announce the opening of its new technology development center in Carlsbad, California, in May 2024. The Carlsbad site is equipped to accelerate customer projects in the fields of cardiovascular…
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
– Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accepted for the International Symposium on Amyloidosis in May 2024
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. “I’m incredibly proud of […]
Tustin, Ca, May 01, 2024 (GLOBE NEWSWIRE) — Canon Medical Systems proudly announces the debut installation of the Aquilion Serve SP CT scanner with INSTINX, AI-driven workflow automation, in the United States at Steinberg Diagnostic Medical Imaging (SDMI), Las Vegas, NV. The Aquilion Serve SP CT scanner combines top-tier imaging […]
Caesarea, Israel – April 30, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, is announcing its partnership with Shandong Yituo Medical Technology Development Co. Ltd. (SYMT), a JMC-invested company. Its new joint venture company, Arineta (Shandong) Medical Equipment Co. Ltd., is anticipating the installation of […]
Award supports design and preclinical testing of Pulmonary Flow Restrictor for Congenital Heart Disease SAN DIEGO, May 1, 2024 /PRNewswire/ — Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business…
